Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: Considerations for their use

Toxicological Sciences

Volumn 117, Issue 1, 2010, Pages 4-16

  Tarrant, Jacqueline M ^a  

^a GENENTECH INC   (United States)

Author keywords

Biomarker; Cytokines; Multiplex immunoassay; Qualification; Risk assessment; Safety; Toxicity; Validation

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PARACETAMOL; PHARMACOLOGICAL BIOMARKER; PHOSPHODIESTERASE INHIBITOR; RANTES; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; SCH 534385; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN ANTIBODY REACTION; COMPETITIVE INHIBITION; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IMMUNOTOXICITY; IN VIVO STUDY; INFLAMMATION; METHODOLOGY; NONHUMAN; PERIODONTAL DISEASE; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; TOXICITY TESTING; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS; VASCULITIS;

ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; RISK ASSESSMENT; TOXICITY TESTS;

EID: 77955883077     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq134     Document Type: Review

References (61)

1. Anderson, P. (2008). Post-transcriptional control of cytokine production. Nat. Immunol. 9, 353-359.
2. Baena, A., Mootnick, A. R., Falvo, J. V., Tsytskova, A. V., Ligeiro, F., Diop, O. M., Brieva, C., Gagneux, P., O'Brien, S. J., Ryder, O. A., et al. (2007). Primate TNF promoters reveal markers of phylogeny and evolution of innate immunity. PLoS One 2, e621.
3. Bezbradica, J. S., and Medzhitov, R. (2009). Integration of cytokine and heterologous receptor signaling pathways. Nat. Immunol. 10, 333-339.
4. Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95.
5. Boehlen, F., and Clemetson, K. J. (2001). Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus. Med. 11, 403-417.
6. Bonecchi, R., Galliera, E., Borroni, E. M., Corsi, M. M., Locati, M., and Mantovani, A. (2009). Chemokines and chemokine receptors: an overview. Front. Biosci. 14, 540-551.
7. Brannstrom, M., Friden, B. E., Jasper, M., and Norman, R. J. (1999). Variations in peripheral blood levels of immunoreactive tumor necrosis factor alpha (TNFalpha) throughout the menstrual cycle and secretion of TNFalpha from the human corpus luteum. Eur. J. Obstet. Gynecol. Reprod. Biol. 83, 213-217.
8. Cannon, J. G. (2000). Inflammatory cytokines in nonpathological states. News Physiol. Sci. 15, 298-303.
9. Cavarra, E., Carraro, F., Fineschi, S., Naldini, A., Bartalesi, B., Pucci, A., and Lungarella, G. (2004). Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L1186-L1192.
10. Chowdhury, F., Williams, A., and Johnson, P. (2009). Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J. Immunol. Methods 340, 55-64.
11. de Jager, W., and Rijkers, G. T. (2006). Solid-phase and bead-based cytokine immunoassay: a comparison. Methods 38, 294-303.
12. de Lemos Rieper, C., Galle, P., and Hansen, M. B. (2009). Characterization and potential clinical applications of autoantibodies against cytokines. Cytokine Growth Factor Rev. 20, 61-75.
13. Dietsch, G. N., Dipalma, C. R., Eyre, R. J., Pham, T. Q., Poole, K. M., Pefaur, N. B., Welch, W. D., Trueblood, E., Kerns, W. D., and Kanaly, S. T. (2006). Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol. Pathol. 34, 39-51.
14. Ellington, A. A., Kullo, I. J., Bailey, K. R., and Klee, G. G. (2009). Measurement and quality control issues in multiplex protein assays: a case study. Clin. Chem. 55, 1092-1099.
15. European Medicines Agency (EMEA). (2007). Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. European Medicines Agency: Committee for Medicinal Products for Human Use Available at: http://www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf. Accessed November, 2009.
16. European Medicines Agency (EMEA). (2008). Final Report on the Pilot Joint EMEA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers Available at: http://www.ema.europa.eu/pdfs/human/biomarkers /25088508en.pdf. Accessed November, 2009.
17. Food and Drug Administration (FDA). (2006). Innovation or Stagnation: Critical Path Opportunities Report and List Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm. Accessed November, 2009.
18. Food and Drug Administration (FDA). (2007). Guidance on Pharmacogenetic Tests and Genetic Tests for Heritable Markers. Available at: http: //www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Guidance Documents/ucm077862.htm. Accessed November 2009.
19. Goodsaid, F. M., Frueh, F. W., and Mattes, W. (2008). Strategic paths for biomarker qualification. Toxicology 245, 219-223.
20. Gorska, R., Gregorek, H., Kowalski, J., Laskus-Perendyk, A., Syczewska, M., and Madalinski, K. (2003). Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. J. Clin. Periodontol. 30, 1046-1052.
21. Grainger, D. J. (2007). TGF-beta and atherosclerosis in man. Cardiovasc. Res. 74, 213-222.
22. Gribble, E. J., Sivakumar, P. V., Ponce, R. A., and Hughes, S. D. (2007). Toxicity as a result of immunostimulation by biologics. Expert Opin. Drug Metab. Toxicol. 3, 209-234.
23. Haddad, J. J. (2002). Cytokines and related receptor-mediated signaling pathways. Biochem. Biophys. Res. Commun. 297, 700-713.
24. Hosnijeh, F. S., Krop, E. J., Portengen, L., Rabkin, C. S., Linseisen, J., Vineis, P., and Vermeulen, R. (2009). Stability and reproducibility of simultaneously detected plasma and serum cytokine levels in asymptomatic subjects. Biomarkers 15, 140-148.
25. International Conference on Harmonization. (2006). International Conference on Harmonization (ICH)-Guidance for Industry: S8 Immunotoxicity Studies for Human Pharmaceuticals Available at: http://www.fda.gov/Regulatory Information/Guidances/ucm129118.htm. Accessed November, 2009.
26. James, L. P., Simpson, P. M., Farrar, H. C., Kearns, G. L., Wasserman, G. S., Blumer, J. L., Reed, M. D., Sullivan, J. E., and Hinson, J. A. (2005). Cytokines and toxicity in acetaminophen overdose. J. Clin. Pharmacol. 45, 1165-1171.
27. Kellar, K. L., and Iannone, M. A. (2002). Multiplexed microsphere-based flow cytometric assays. Exp. Hematol. 30, 1227-1237.
28. Keller, M., Mazuch, J., Abraham, U., Eom, G. D., Herzog, E. D., Volk, H. D., Kramer, A., and Maier, B. (2009). A circadian clock in macrophages controls inflammatory immune responses. Proc. Natl. Acad. Sci. U. S. A. 106, 21407-21412.
29. Kenis, G., Teunissen, C., De Jongh, R., Bosmans, E., Steinbusch, H., and Maes, M. (2002). Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine 19, 228-235.
30. Kerns, W., Schwartz, L., Blanchard, K., Burchiel, S., Essayan, D., Fung, E., Johnson, R., Lawton, M., Louden, C., MacGregor, J., et al. (2005). Drug-induced vascular injury-a quest for biomarkers. Toxicol. Appl. Pharmacol. 203, 62-87.
31. Khan, I. H., Krishnan, V. V., Ziman, M., Janatpour, K., Wun, T., Luciw, P. A., and Tuscano, J. (2009). A comparison of multiplex suspension array largepanel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin. Cytom. 76, 159-168.
32. Khan, S. S., Smith, M. S., Reda, D., Suffredini, A. F., and McCoy, J. P., Jr. (2004). Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin. Cytom. 61, 35-39.
33. Kovar, F. M., Marsik, C., Cvitko, T., Wagner, O. F., Jilma, B., and Endler, G. (2007). The tumor necrosis factor alpha -308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock 27, 238-241.
34. Lacour, S., Gautier, J. C., Pallardy, M., and Roberts, R. (2005). Cytokines as potential biomarkers of liver toxicity. Cancer Biomark. 1, 29-39.
35. LaPorte, S. L., Juo, Z. S., Vaclavikova, J., Colf, L. A., Qi, X., Heller, N. M., Keegan, A. D., and Garcia, K. C. (2008). Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132, 259-272.
36. Lee, J. W., and Hall, M. (2009). Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 1259-1271.
37. Lee, J. W., Weiner, R. S., Sailstad, J. M., Bowsher, R. R., Knuth, D. W., O'Brien, P. J., Fourcroy, J. L., Dixit, R., Pandite, L., Pietrusko, R. G., et al. (2005). Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 22, 499-511.
38. Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., and Ryan, J. L. (1997). Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541-2548.
39. Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature 454, 428-435.
40. Medzhitov, R., and Horng, T. (2009). Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 9, 692-703.
41. Mestas, J., and Hughes, C. C. (2004). Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738.
42. Modi, W. S., and Yoshimura, T. (1999). Isolation of novel GRO genes and a phylogenetic analysis of the CXC chemokine subfamily in mammals. Mol. Biol. Evol. 16, 180-193.
43. Muller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flugel, A., and Reichardt, H. M. (2008). A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J. Clin. Invest. 118, 1405-1416.
44. Muller, P. Y., and Brennan, F. R. (2009). Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin. Pharmacol. Ther. 85, 247-258.
45. Niwa, Y., Akamatsu, H., Sumi, H., Ozaki, Y., and Abe, A. (2000). Evidence for degradation of cytokines in the serum of patients with atopic dermatitis by calcium-dependent protease. Arch. Dermatol. Res. 292, 391-396.
46. Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., and Marincola, F. M. (2004). Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. 2, 17.
47. Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., and Chrousos, G. P. (1998). The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128, 127-137.
48. Piccotti, J. R., Lebrec, H. N., Evans, E., Herzyk, D. J., Hastings, K. L., Burns-Naas, L. A., Gourley, I. S., Wierda, D., and Kawabata, T. T. (2009). Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs. J. Immunotoxicol. 6, 1-10.
49. Rajnik, M., Salkowski, C. A., Thomas, K. E., Li, Y. Y., Rollwagen, F. M., and Vogel, S. N. (2002). Induction of early inflammatory gene expression in a murine model of nonresuscitated, fixed-volume hemorrhage. Shock 17, 322-328.
50. Rakhit, A., Yeon, M. M., Ferrante, J., Fettner, S., Nadeau, R., Motzer, R., Bukowski, R., Carvajal, D. M., Wilkinson, V. L., Presky, D. H., et al. (1999). Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin. Pharmacol. Ther. 65, 615-629.
51. Ray, C. A., Bowsher, R. R., Smith, W. C., Devanarayan, V., Willey, M. B., Brandt, J. T., and Dean, R. A. (2005). Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J. Pharm. Biomed. Anal. 36, 1037-1044.
52. Robertson, M. J., Mier, J. W., Logan, T., Atkins, M., Koon, H., Koch, K. M., Kathman, S., Pandite, L. N., Oei, C., Kirby, L. C., et al. (2006). Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12, 4265-4273.
53. Smith, A. J., and Humphries, S. E. (2009). Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 20, 43-59.
54. St Ledger, K., Agee, S. J., Kasaian, M. T., Forlow, S. B., Durn, B. L., Minyard, J., Lu, Q. A., Todd, J., Vesterqvist, O., and Burczynski, M. E. (2009). Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. J. Immunol. Methods 350, 161-170.
55. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., and Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028.
56. Toedter, G., Hayden, K., Wagner, C., and Brodmerkel, C. (2008). Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin. Vaccine Immunol. 15, 42-48.
57. Warle, M. C., van der Laan, L. J., Kusters, J. G., Pot, R. G., Hop, W. C., Segeren, K. C., Ijzermans, J. N., Metselaar, H. J., and Tilanus, H. W. (2005). No association between tumor necrosis factor-alpha production and gene polymorphisms among inbred rat strains. Transpl. Immunol. 14, 77-82.
58. Watanabe, M., Uchida, K., Nakagaki, K., Kanazawa, H., Trapnell, B. C., Hoshino, Y., Kagamu, H., Yoshizawa, H., Keicho, N., Goto, H., et al. (2007). Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 581, 2017-2021.
59. Weaver, J. L., Snyder, R., Knapton, A., Herman, E. H., Honchel, R., Miller, T., Espandiari, P., Smith, R., Gu, Y. Z., Goodsaid, F. M., et al. (2008). Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385. Toxicol. Pathol. 36, 840-849.
60. Wong, H. L., Pfeiffer, R. M., Fears, T. R., Vermeulen, R., Ji, S., and Rabkin, C. S. (2008). Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol. Biomarkers Prev. 17, 3450-3456.
61. Woodcock, J., and Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1-12.